Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiCAR Therapy: glofitamab after CAR T-cell therapy failure in relapsed/refractory lymphoma
2023-508301-25-00Phase 2Completed
- Sponsor
- LYSARC
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab and obinutuzumab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and 2 more, sponsored by LYSARC. Primary endpoint: Overall survival. Started Nov 2023; status: completed.
02
Drugs
glofitamabobinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)mantle cell lymphoma (MCL)indolent lymphomaTransformed Indolent Non-Hodgkin Lymphoma
Beyond the preview
Go deeper on 2023-508301-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508301-25-00.